SS
CLRB icon

SBI Securities’s Cellectar Biosciences CLRB Stock Holding History

SBI Securities’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31 Hold
11
– – ﹤0.01% 3767
2026
Q1 		$28 Hold
11
– – ﹤0.01% 3690
2025
Q4 		$32 Hold
11
– – ﹤0.01% 3675
2025
Q3 		$62 Hold
11
– – ﹤0.01% 3648
2025
Q2 		$78 Sell
11
-2
-15% -$17 ﹤0.01% 3608
2025
Q1 		$126 Hold
13
– – ﹤0.01% 3374
2024
Q4 		$120 Buy
+13
New +$601 ﹤0.01% 3404

Other funds holding CLRB

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $349M AUM 33.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

SBI Securities's CLRB Position: Q2 2026 in Review

SBI Securities held its Cellectar Biosciences (CLRB) position steady in Q2 2026 at 11 shares worth $31. The position accounts for ﹤0.01% of the portfolio, ranked #3767.

SBI Securities first reported a position in CLRB in Q4 2024 and has held it in 7 quarters since. The position peaked at $126 in Q1 2025. 18 funds tracked by Wall St. Rank hold CLRB as of Q2 2026.

  • SBI Securities held 11 shares of Cellectar Biosciences worth $31 as of Q2 2026.
  • SBI Securities left its Cellectar Biosciences share count unchanged in Q2 2026.
  • Cellectar Biosciences made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3767 holding.
  • SBI Securities first reported a position in Cellectar Biosciences in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Cellectar Biosciences position peaked at $126 in Q1 2025.
  • 18 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.